Antithymocyte globulin followed by cyclosporine for the treatment of acute GVHD in patients given HLA-identical or -nonidentical marrow grafts
Graft-v-host disease (GVHD) remains a major complication after allogeneic marrow transplantation. Between 30% and 60% of patients given unmanipulated marrow from an HLA-identical sibling donor and 80% of patients transplanted from an HLA-nonidentical donor and given postgrafting immunosuppression with a single agent develop acute GVHD requiring therapy. We carried out a study in which patients with acute GVHD were given ATG followed by CsA with or without the addition of MP. Two thirds of patients responded to therapy, and long-term survival was better than in patients treated in the past with single-agent therapy. This report presents follow-up data on the patient population observed now for 15 to 30 months after transplantation.